Has Daniel Gossett received payments from drug or device companies?

Yes. Drug and device makers reported $35,715 in general payments to Daniel Gossett across 763 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Daniel Gossett did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Daniel Gossett come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Daniel Gossett

Neurology with Special Qualifications in Child Neurology · Dallas, TXNPI 1588980072

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Immedica Pharma US, Inc. at 44.6% of the total. Reporting peaked in 2024 at $14,852 and has fallen 84.0% since, to $2,369 in 2025. Among neurology with special qualifications in child neurology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$35,715in general payments, 2019–2025

Across 763 payments — averaging $46.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Immedica Pharma US, Inc.$16K
Biomarin Pharmaceutical Inc.$5K
UCB, Inc.$2K
Ironshore Pharmaceuticals Inc.$1K
Natus Medical Incorporated$1K
Eisai Inc.$1K
plus $10K from 54 others

What the payments were for

Speaking & faculty fees$20,04656%
Travel & lodging$6462%
Food & beverage$14,98242%
Education$410%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Immedica Pharma US, Inc.	36	$15,935
Biomarin Pharmaceutical Inc.	9	$5,118
UCB, Inc.	79	$1,511
Ironshore Pharmaceuticals Inc.	65	$1,092
Natus Medical Incorporated	2	$1,012
Eisai Inc.	54	$1,008
Supernus Pharmaceuticals, Inc.	66	$891
Livanova USA, Inc.	27	$817
Jazz Pharmaceuticals Inc.	33	$710
Neurelis, Inc.	39	$688
Tris Pharma Inc	35	$556
Corium, LLC	22	$461
SK Life Science, Inc.	18	$447
Neos Therapeutics, LP	24	$432
Sunovion Pharmaceuticals Inc.	23	$384
Acadia Pharmaceuticals Inc	15	$343
Aquestive Therapeutics, Inc.	19	$294
Argenx US, Inc.	8	$273
Merz Pharmaceuticals, LLC	8	$256
AbbVie(2 entities)	12	$239
Takeda Pharmaceuticals U.S.A., Inc.	11	$238
Adlon Therapeutics L.p.	15	$212
Sumitomo Pharma America, Inc.	11	$187
Zogenix Inc.	8	$180
Neurocrine Biosciences, Inc.	6	$177
Biohaven Pharmaceuticals, Inc.	10	$166
Teva Pharmaceuticals USA, Inc.	5	$164
Aprecia Pharmaceuticals, LLC	9	$161
Biogen	7	$141
Ipsen Biopharmaceuticals, Inc	5	$129
TG Therapeutics, Inc.	6	$121
AstraZeneca	4	$86
Catalyst Pharmaceuticals, Inc.	5	$84
Octapharma USA, Inc.	3	$74
Grifols USA, LLC	3	$74
Arbor Pharmaceuticals, Inc.	5	$65
Amneal Pharmaceuticals LLC	3	$60
Shire North American Group Inc	4	$59
Collegium Pharmaceutical, Inc.	3	$59
Avion Pharmaceuticals	3	$51
Sanofi	2	$49
Lundbeck LLC	3	$48
NS Pharma, Inc.	2	$47
Travere Therapeutics, Inc.	4	$46
PTC Therapeutics, Inc.	2	$43
Cranial Technologies, Inc	3	$41
ANI Pharmaceuticals, Inc.	2	$41
Kedrion Biopharma, Inc.	2	$40
Springworks Therapeutics, Inc.	2	$35
Biohaven Pharmaceutical Holding Company Ltd.	2	$32
Sarepta Therapeutics, Inc.	2	$32
Mallinckrodt Enterprises LLC	2	$32
Biocodex, Inc.	1	$30
Aucta Pharmaceuticals, Inc.	2	$29
Azurity Pharmaceuticals, Inc.	1	$26
Revance Therapeutics, Inc.	1	$24
Abbott	1	$22
Lilly USA, LLC	1	$21
CSL Behring	1	$20
Noven Therapeutics, LLC	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ZTALMY$15,293
Brineura$109
VNS THERAPY SENTIVA MODEL 1000 GENERATOR$100

How this compares

$35,715 in reported general payments places this provider in the 90th percentile of 193 neurology with special qualifications in child neurology providers in Texas.

See all neurology with special qualifications in child neurology providers in Texas →

Other neurology with special qualifications in child neurology in Dallas

Roy EltermanDallas$5.9M
Raphael SchiffmannDallas$88K
Mauricio Delgado-AyalaDallas$75K
Kaitlin BatleyDallas$74K
Zurisadai Gonzalez CastilloDallas$30K
Steven SparaganaDallas$7K
Berge MinassianDallas$5K
Charuta JoshiDallas$4K
David OwenDallas$4K
Deepa SirsiDallas$3K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →